Hierro, C., et al. FGFR1-4 High mRNA Expression (mRNAh) as Predictive Biomarker for FGFR Inhibitors in Breast Cancer (BC). Annals of Oncology 2020 MAR:31(S1),S8-S9., Abstract 29P.
Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)
Lenz, A., et al. CCR5 Δ32 Mutation and Gene Expression to Predict Outcome in Patients (pts) with Metastatic Colorectal Cancer (mCRC): Data From FIRE-3 and MAVERICC Phase III Trials. Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)
Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.
Dora, D., et al. Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribtution. bioRxiv preprint 2020 Feb 3. doi:https://doi.org/10.1101/2020.02.02.930305
Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.
Softic, S., et al. Dietary Sugars Alter Hepatic Fatty Acid Oxidation via Transcriptional and Post-translational Modifications of Mitochondrial Proteins. Cell Metabolism 2019; 30, 735-753.
Tong, C., et al. Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma using next-generation sequencing. International Forum of Allergy & Rhinology 2019; 9(2):S56.
Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland. Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629
William, N. W., et al. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). Presented Clinical Science Symposium, American Society of Clinical Oncology (ASCO) Annual Meeting; June 2, 2019, Chicago, IL. Abstract # 6009
Valverde Morales, C. M., et al. Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): a joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study. American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL
Hurwitz, M. E., et al. Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019, Chicago, IL
Page last updated May 22, 2023